Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations (Unaudited)

v3.19.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Revenue:    
Contract research revenue $ 29,937
Costs and expenses:    
Research and development 2,314,701 2,192,888
General and administrative 1,788,414 1,957,798
Total costs and expenses 4,103,115 4,150,686
Loss from operations (4,103,115) (4,120,749)
Other income, net 52,407 10,745
Net loss (4,050,708) (4,110,004)
Preferred stock series A accumulated dividends (146,786) (147,286)
Preferred stock series B accumulated dividends (118,250)
Net loss attributable to common shareholders $ (4,315,744) $ (4,257,290)
Net loss available for common shareholders per share - basic and diluted $ (0.04) $ (0.05)
Weighted average common shares outstanding - basic and diluted 117,366,673 93,542,552